Navigation Links
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Date:10/19/2007

IRVINE, Calif., Oct. 19 /PRNewswire/ -- Xytis Inc., a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases, today announced that Gordon H. Busenbark has joined the company as Chief Financial Officer. Mr. Busenbark has more than 25 years of experience in the pharmaceutical, biotechnology and medical devices industries. During a 23 year career at Baxter Healthcare, Mr. Busenbark held a number of senior-level financial, operational and general management positions in both the U.S. and Europe. This included roles as Chief Financial Officer of Immuno AG when the company was acquired by Baxter, and President of Baxter's global Plasma Therapeutics business. Mr. Busenbark's most recent role was as Chief Financial Officer at Encysive Pharmaceuticals, where his accomplishments included raising more than $100 million in debt and equity financing.

"We are very pleased to have Gordon join Xytis," said Vincent F. Simmon, CEO and President. "He brings great financial and operational experience, both from a large pharmaceutical company perspective as well as from that of a smaller biotechnology company. Gordon joins us at an exciting time for Xytis. Our Phase 2 clinical trial in Traumatic Brain Injury (TBI) is approximately half way enrolled. Also, there is considerable partnering interest in two of our pre-clinical programs; positive allosteric modulators of GABA-A receptor and of alpha-7 nicotinic acetylcholine receptors. His experience and assistance in financing and marshalling these programs forward will be greatly welcomed."

Mr. Busenbark has both a B.S. in Accounting and an MBA from the University of Utah.

About Xytis

Xytis Inc. is a privately held discovery and development biopharmaceutical company, headquartered in Irvine, California, and having a clinical development group in Nyon, Switzerland, focused on innovative CNS drug candidates. The Company's investors include At
'/>"/>

SOURCE Xytis Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014   NxStage® Kidney Care, Inc ., a ... is proud to host the grand opening ceremony of its ... W. 16 th Street on November 20, 2014 from ... trained medical staff who are committed to providing patients with ... benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... Oct. 30, 2014 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... release third quarter 2014 financial results on Wednesday, November ... The Company,s management will hold a conference call at ... which is 8:30 p.m., Beijing Time on November 6, ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2
... Reportlinker.com announces that a new market research ... European Markets for Dental Bone Graft Substitutes, ... http://www.reportlinker.com/p0339837/European-Markets-for-Dental-Bone-Graft-Substitutes-Dental-Membranes-and-Tissue-Engineering-2011.html In ... graft substitutes and other biomaterials grew by 4.4% ...
... (Nasdaq: VRNM ), a pioneer in the ... today announced key 2010 accomplishments and 2011 Company ... a significant year of transition for Verenium as we ... building the next leading industrial enzymes company," said Carlos ...
Cached Medicine Technology:Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 2Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 3Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 4Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 5Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 6Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 7Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 8Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 9Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 10Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 11Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 12Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 13Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 14Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 15Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 16Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 17Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 18Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 19Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 20Verenium Announces 2010 Business Update and Outlook for 2011 2Verenium Announces 2010 Business Update and Outlook for 2011 3Verenium Announces 2010 Business Update and Outlook for 2011 4Verenium Announces 2010 Business Update and Outlook for 2011 5
(Date:10/30/2014)... Five months after their expansion, the AV ... branding and a website to accompany their recent change ... promotion to name partner earlier this year, Hodgkinson Street ... name and better reflect their combined litigation expertise. As ... to implement new branding reflects Hodgkinson Street Mepham’s collaborative ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... California (PRWEB) October 30, 2014 REV'D ... bars are now available through a unique service called, ... site designed to empower the everyday athlete. The Feed ... best athletes and created a system to pass that ... to see REV’D® is now available on The Feed!” ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3
... dysfunctions- painful intercourse, sexual dissatisfaction and a multitude ... the patients and their doctors communicated better, most ... all women, as they go through menopause, will ... known as genital atrophy. ,This results in ...
... back with a vengeance. The killer disease of the past is ... partner in its destructive mission. Full-blown cases of AIDS coupled with ... in Africa alone. What is alarming is that the death rate ... no signs of the destruction slowing down. ,Health experts argue ...
... deaths due to asthma can be prevented if the ... disease. According to WHO, around 150 million people suffer ... due to the disease every year. Asthma is a ... characterized by sudden recurring attacks of labored breathing, chest ...
... that wound healing in depressed people is four times slower ... a place in the latest issue of the journal, “Psychosomatic ... on the rate of wound healing, according to the researchers. ... the immune system, which may keep a wound from healing ...
... injure the donor, it is now established without doubt that a ... person needing it. And the good news is that the donor ... his/her liver. ,Donation of a piece of the liver's right ... It is increasingly being performed in the West where the demand ...
... for the treatment of cancer has nearly,doubled during ... survey of pharmaceutical,companies.,Currently, 170 pharmaceutical and biotechnology firms ... treatment of various,cancers, up from 215 in 1995. ... and chemotherapy. For lung cancer, the leading cause ...
Cached Medicine News:
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
... ANA and ENA assays can be ... for antinuclear antibodies, which are associated ... as Systemic lupus erythematosus (Lupus), Sjgren's ... systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and ...
... ANA and ENA assays can be ... for antinuclear antibodies, which are associated ... as Systemic lupus erythematosus (Lupus), Sjgren's ... systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
Medicine Products: